Table of Content

1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Chronic Diseases
4.2.2. Innovations in PoC Tests
4.2.3. Development of CLIA-waived PoC Tests
4.2.4. Lack of Skilled Technicians for Performing Lab Tests
4.3. Restraints
4.3.1. Pricing Pressure Due to Fluctuations in Reimbursements
4.4. Opportunities
4.4.1. Emerging Markets
4.4.2. Healthcare Professionals’ Increasing Preference for PoC Tests Over Other Lab Tests
4.5. Challenges
4.5.1. Lack of Awareness Regarding the Use of PoC Devices
4.6. Technology Trends
4.6.1. Lateral Flow Assays Containing DNA Nanostructures
4.6.2. Rapid Real-time Polymerization Chain Reaction (PCR) Tests
4.6.3. Smartphone-based Detection Platforms
4.6.4. Nanoelectronic Biosensors in Point-of-Care Diagnostics
4.7. Regulatory Analysis
4.7.1. U.S.
4.7.2. Canada
4.7.3. Europe
4.7.4. China
4.7.5. Japan
4.7.6. Latin America
4.7.7. Saudi Arabia
4.8. Pricing Analysis

5. Point-of-Care Diagnostics Market Assessment?by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software And Services

6. Point-of-Care Diagnostics Market Assessment?by Platform
6.1. Overview
6.2. Lateral Flow Assays
6.3. Molecular Diagnostics
6.4. Other Platforms

7. Point-of-Care Diagnostics Market Assessment?by Application
7.1. Overview
7.2. Blood Glucose Monitoring
7.3. Infectious Disease Testing
7.3.1. Parasitic Infections Testing
7.3.2. Blood-borne Infections Testing
7.3.2.1. Hepatitis
7.3.2.2. HIV
7.3.2.3. Other Blood-borne Infections
7.3.3. Respiratory Infections Testing
7.3.3.1. Influenza
7.3.3.2. Pneumonia
7.3.3.3. Tuberculosis (TB)
7.3.3.4. Other Respiratory Infections Testing
7.3.4. Healthcare-associated Infections (HAI) Testing
7.3.5. Gastrointestinal Infections Testing
7.3.5.1. Salmonellosis
7.3.5.2. E. Coli Infections
7.3.5.3. Other GI Infections
7.3.6. Other Infectious Diseases Testing
7.4. COVID-19 Testing
7.5. Tumor/Cancer Markers Testing
7.6. Pregnancy And Fertility Testing
7.6.1. Pregnancy Testing
7.6.2. Fertility Testing
7.7. Cardiac Marker/Cardiac Metabolism Testing
7.8. Cholesterol/Lipid Profile Testing
7.9. Coagulation Testing
7.9.1. Prothrombin Time (PT/INR) Testing
7.9.2. Activated Clotting Time (ACT/APTT) Testing
7.9.3. Other Coagulation Testing
7.10. Hematology
7.11. Drugs of Abuse Testing
7.12. Urinalysis
7.13. Other PoC Testing

8. Point-of-Care Diagnostics Market Assessment?by Sample Type
8.1. Overview
8.2. Blood Sample
8.3. Nasopharyngeal Swab
8.4. Urine Sample
8.5. Saliva Sample
8.6. Other Sample Types

9. Point-of-Care Diagnostics Market Assessment?by End User
9.1. Overview
9.2. Hospitals
9.3. Home Care/Self-testing
9.4. Physician Offices & Ambulatory Care Settings
9.5. Diagnostics Laboratories
9.6. Other End Users

10. Point-of-Care Diagnostics Market Assessment?by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa

11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Dashboard
11.3.1. Industry Leaders
11.3.2. Market Differentiators
11.3.3. Vanguards
11.3.4. Emerging Companies
11.4. Market Share Analysis (2022)
11.4.1. Abbott Laboratories
11.4.2. F. Hoffmann-La Roche Ltd
11.4.3. Siemens Healthineers AG
11.4.4. Danaher Corporation
11.4.5. Thermo Fisher Scientific, Inc.

12. Company Profiles
12.1. Abbott Laboratories
12.2. F. Hoffmann-La Roche Ltd
12.3. Siemens Healthineers AG
12.4. Danaher Corporation
12.5. Thermo Fisher Scientific Inc.
12.6. Becton, Dickinson and Company (BD)
12.7. bioM?rieux S.A.
12.8. QuidelOrtho Corporation
12.9. EKF Diagnostics Holdings plc
12.10. Sekisui Diagnostics, LLC.
12.11. Trinity Biotech plc
12.12. Chembio Diagnostics, Inc.
12.13. Werfen
12.14. Nova Biomedical
13. Appendix
13.1. Available Customization
13.2. Related Reports



List of Figures

List of Figures
Figure 1 Research process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation and Growth Forecast Approach
Figure 7 Global Point-of-Care Diagnostics Market, by Offering, 2023 Vs. 2030
Figure 8 Global Point-of-Care Diagnostics Market Size, by Sample Type, 2023 Vs. 2030 (USD Million)
Figure 9 Global Point-of-Care Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global Point-of-Care Diagnostics Market, by Platform, 2023 Vs. 2030
Figure 11 Global Point-of-Care Diagnostics Market, by End User, 2023 Vs. 2030
Figure 12 Global Point-of-Care Diagnostics Market, by Geography
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Global Percentage Share of the Population Aged 65 Years and Above
Figure 15 Population Aged 65 years or Over, by Region, 2020 VS. 2030 (In Million)
Figure 16 EU Regulatory Pathway - IVDR 2017/746
Figure 17 China: Medical Device Classification and Pre-Market Requirements for PoC Diagnostic Devices
Figure 18 Global Point-of-Care Diagnostics Market, by Offering, 2023 VS. 2030
Figure 19 Global Point-of-Care Diagnostics Market, by Platform, 2023 VS. 2030
Figure 20 Global Point-of-Care Diagnostics Market, by Application, 2023 VS. 2030
Figure 21 Prevalence of Diabetes Across the World: 2015–2045 (In Million)
Figure 22 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Million)
Figure 23 Global Point-of-Care Diagnostics Market, by Sample Type, 2023 VS. 2030
Figure 24 Benefits of Saliva Sampling
Figure 25 Global Point-of-Care Diagnostics Market, by End User, 2023 VS. 2030
Figure 26 U.S.: Home Healthcare Spending, 2015–2026 (USD Million)
Figure 27 Point-of-Care Diagnostics Market, by Region, 2023 VS. 2030 (USD Million)
Figure 28 North America: Point-of-Care Diagnostics Market Snapshot
Figure 29 U.S.: Number of HIV-positive Patients, 2017–2020
Figure 30 Canada: Number of People Aged 65 Years and Above, 2018–2022 (In Thousand)
Figure 31 Canada: Number of Inpatient Admissions in Acute-Care Hospitals, 2016–2020 (per 100,000 Population)
Figure 32 Europe: Point-of-Care Diagnostics Market Snapshot
Figure 33 France: Percentage of Population Aged 65 Years and Above, 2016–2020
Figure 34 U.K: Estimated Number of Cancer Cases, 2020–2030
Figure 35 U.K.: Number of Diabetes and Urogenital, Blood, and Endocrine Diseases Cases - DALYs (Disability-Adjusted Life Years), 2017–2020 (in Thousand)
Figure 36 U.K.: Number of People Diagnosed with Sexually Transmitted Infections
Figure 37 Italy: Prevalence of Healthcare-Associated Infections in Acute-Care Wards, 2016–2019
Figure 38 Italy: Ovarian Cancer Cases: 2018–2030
Figure 39 Number of HIV Tests Performed in Catalonia (Spain), 2014–2020
Figure 40 Health Expenditure (2015–2020)
Figure 41 Asia-Pacific: Point-of-Care Diagnostics Market Snapshot
Figure 42 China: Independent Medical Laboratories Market, 2015–2019 (USD Million)
Figure 43 Japan: Percentage Growth in the Aging Population (2015–2021)
Figure 44 Latin America: Point-of-Care Diagnostics Market Snapshot
Figure 45 Brazil: People Living with HIV
Figure 46 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 47 Competitive Dashboard: Point-of-Care Diagnostics Market
Figure 48 Market Share Analysis: Point-of-Care Diagnostics Market (2022)
Figure 49 Financial Overview: Abbott laboratories (2022)
Figure 50 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 51 Siemens Healthineers AG: Financial Overview (2022)
Figure 52 Danaher Corporation: Financial Overview (2022)
Figure 53 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 54 Becton, Dickinson and Company: Financial Overview (2022)
Figure 55 bioM?rieux S.A.: Financial Overview (2022)
Figure 56 QuidelOrtho Corporation: Financial Overview (2022)
Figure 57 EKF Diagnostics Holdings plc: Financial Overview (2022)
Figure 58 Sekisui Chemical Co., Ltd.: Financial Overview (2021)
Figure 59 Trinity Biotech plc: Financial Overview (2021)
Figure 60 Chembio Diagnostics: Financial Overview (2021)
Figure 61 Werfen: Financial Overview (2021)